112 related articles for article (PubMed ID: 29771169)
1. Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.
Brøndum L; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Evensen JF; Kristensen CA; Andersen LJ; Overgaard J; Eriksen JG
Acta Oncol; 2018 Sep; 57(9):1159-1164. PubMed ID: 29771169
[TBL] [Abstract][Full Text] [Related]
2. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
Saloura V; Cohen EE; Licitra L; Billan S; Dinis J; Lisby S; Gauler TC
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1227-39. PubMed ID: 24714973
[TBL] [Abstract][Full Text] [Related]
3. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
5. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
7. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
[TBL] [Abstract][Full Text] [Related]
8. Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T; Perez-Soler R
Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
[TBL] [Abstract][Full Text] [Related]
9. Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab.
Roman J; Dissaux G; Gouillou M; Gobel Y; Potard G; Leclere JC; Conan-Charlet V; Gujral D; Abgral R; Guibourg B; Pradier O; Schick U
Target Oncol; 2017 Aug; 12(4):505-512. PubMed ID: 28580506
[TBL] [Abstract][Full Text] [Related]
10. Rash conclusions from a phase 3 study of cetuximab?
Harrington KJ
Lancet Oncol; 2010 Jan; 11(1):2-3. PubMed ID: 20129123
[No Abstract] [Full Text] [Related]
11. p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis.
Su Y; Cui J; Xu D; Wang M; Xu T; Tian H; Han F
Crit Rev Oncol Hematol; 2018 Apr; 124():11-20. PubMed ID: 29548481
[TBL] [Abstract][Full Text] [Related]
12. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.
Rodríguez MO; Rivero TC; del Castillo Bahi R; Muchuli CR; Bilbao MA; Vinageras EN; Alert J; Galainena JJ; Rodríguez E; Gracias E; Mulén B; Wilkinson B; de Armas EL; Pérez K; Pineda I; Frómeta M; Leonard I; Mullens V; Viada C; Luaces P; Torres O; Iznaga N; Crombet T
Cancer Biol Ther; 2010 Mar; 9(5):343-9. PubMed ID: 20448462
[TBL] [Abstract][Full Text] [Related]
13. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
Jaka A; Gutiérrez-Rivera A; Ormaechea N; Blanco J; La Casta A; Sarasqueta C; Izeta A; Tuneu A
Exp Dermatol; 2014 Oct; 23(10):751-3. PubMed ID: 25039761
[TBL] [Abstract][Full Text] [Related]
14. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
Lee Y; Shim HS; Park MS; Kim JH; Ha SJ; Kim SH; Cho BC
Clin Cancer Res; 2012 Mar; 18(6):1760-8. PubMed ID: 22271877
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Parmar S; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seeringer A; Paul T; Seufferlein T; Stingl JC
Pharmacogenomics J; 2013 Apr; 13(2):181-8. PubMed ID: 22158333
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
18. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
[TBL] [Abstract][Full Text] [Related]
19. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan
Chen L; Brown J; Marmaduke DQ; Mayo C; Grau G; Lau YK; Obasaju CK
Support Care Cancer; 2018 Jul; 26(7):2369-2377. PubMed ID: 29423677
[TBL] [Abstract][Full Text] [Related]
20. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival.
Azad AK; Bairati I; Samson E; Cheng D; Mirshams M; Qiu X; Savas S; Waldron J; Wang C; Goldstein D; Xu W; Meyer F; Liu G
Clin Cancer Res; 2012 Jan; 18(1):196-206. PubMed ID: 22076708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
